FDA Approves Teplizumab for Children with New-Onset Type 1 Diabetes

Teplizumab is a monoclonal antibody—a type of immune protein—that targets CD3 on T cells. These immune cells play a key role in the autoimmune attack that destroys insulin-producing beta cells in type 1 diabetes. By modulating this immune response, teplizumab is designed to slow the loss of remaining beta-cell function.

The drug was first approved by the FDA in November 2022 for people ages 8 and older with stage 2 type 1 diabetes—a preclinical phase marked by the presence of multiple diabetes-related autoantibodies and changes in blood sugar, but before symptom onset. In April 2026, that approval was extended to children as young as 1 year old. The newly approved stage 3 indication now covers children and adolescents ages 8–17 with newly diagnosed, clinical-stage type 1 diabetes.

The stage 3 approval was based primarily on the PROTECT trial, which enrolled 328 children and teens ages 8–17 with new-onset type 1 diabetes (diagnosed within 6 weeks). Participants were randomly assigned to receive either teplizumab or placebo as two 12-day intravenous courses given 6 months apart.

At 78 weeks, children who received teplizumab had a significantly slower decline in C-peptide—a marker of remaining insulin production—compared with those receiving placebo. Nearly 95% of teplizumab-treated children maintained clinically meaningful C-peptide levels, versus about 79% in the placebo group.

An integrated analysis of five stage 3 trials involving 609 participants found that teplizumab treatment led to higher C-peptide levels at one and two years after treatment. Across trials, insulin requirements were also modestly reduced in treated patients compared to controls.

Teplizumab carries a boxed warning—the FDA's most serious safety alert—regarding the risk of viral reactivation. Before starting treatment, patients must be screened for Epstein-Barr virus and cytomegalovirus.

The most commonly reported side effects include rash, vomiting, headache, elevated liver enzymes, and low white blood cell counts (lymphopenia). Many of these symptoms occur during and shortly after the first infusion course and typically resolve without additional treatment.

Cytokine release syndrome—a reaction caused by rapid immune activation—can occur, typically within the first 5 days of treatment. Allergic reactions are also possible. Safety data from approximately 1,500 patient-years of follow-up across clinical trials show a consistent and manageable safety profile.

The approval for stage 3 type 1 diabetes complements teplizumab's existing use in earlier disease stages and reflects growing evidence that delaying immune-mediated beta-cell loss can have clinical benefit. Ongoing research includes studies in diverse populations, such as a phase 2 trial now recruiting Japanese participants with stage 2 type 1 diabetes.

International diabetes organizations, including the International Society for Pediatric and Adolescent Diabetes (ISPAD), have begun incorporating teplizumab into clinical practice guidelines, noting both opportunities and challenges for its use in pediatric populations.

Origin: medscape.com (News report). Evidence: News report, corroborated with 4 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.